MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes. Sormani M P, De Stefano N Mult Scler. 2014 Mar; 20(3):280-1. PMID: 24589685. Abstract CommentRecommendBookmarkWatch